Tag Archives: #FDA

OPDP Issues First Regulatory Action Letter of 2022

FDA’s Office of Prescription Drug Promotion (OPDP) issued the first regulatory action letter for 2022. This one has some notable characteristics. As has been frequently noted, enforcement actions by OPDP have diminished considerably over the years. Another characteristic of recent … Continue reading

Posted in Warning Letters | Tagged , , , | Leave a comment

What They Said 2021 – An Overview of FDA Press Statements

Each year we look back to take stock of how the agency has been communicating in the course of the previous year and assess how that might compare to years gone by. In fact from year to year, there is … Continue reading

Posted in FDA Image, FDA Policy | Tagged , , | Comments Off on What They Said 2021 – An Overview of FDA Press Statements

FDA OPDP Look Back at 2021 – The Yawning Gap

Once again it was a quiet year with respect to the FDA’s Office of Prescription Drug Programs (OPDP). As noted in the past, there are two primary means for understanding the agency’s latest thinking with respect to promotional communications from … Continue reading

Posted in DTC Advertising, FDA, FDA Policy | Tagged , , | Comments Off on FDA OPDP Look Back at 2021 – The Yawning Gap

FDA Authorizes Third Dose – Some Implications

What does “fully vaccinated” mean today? In the face of the widening spread of the SARS-Cov-2 variant, the rise in breakthrough cases, and data that suggests a slight waning effect over time of vaccines, FDA acted yesterday to protect some … Continue reading

Posted in Uncategorized | Tagged , | Comments Off on FDA Authorizes Third Dose – Some Implications

What They Said – FDA Press Releases Mid-2021

It has been a regular feature of the blog to give a read on what FDA has been talking about, at least through the form of press releases. It is not always an easy task because the nature of FDA’s … Continue reading

Posted in FDA, FDA Image | Tagged | Comments Off on What They Said – FDA Press Releases Mid-2021